News stories about Biolase (NASDAQ:BIOL) have been trending somewhat negative recently, according to Accern Sentiment. The research group scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Biolase earned a coverage optimism score of 0.00 on Accern’s scale. Accern also assigned news coverage about the medical technology company an impact score of 47.316288685149 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:
- Stock Trading Watch for Ultragenyx Pharmaceutical Inc (RARE) (vothemes.com)
- Global Dental Equipment Industry is expected to reach $ 7602 Million by 2021 with a CAGR of 5.20% (emailwire.com)
- Globsl $10 Billion Dental Diagnostics & Surgical Equipments Products Markets, 2022 (finanznachrichten.de)
- North America dental equipment market is poised to reach $ 2,138 million by 2021 with a CAGR of 5.3% according to new research report (whatech.com)
- BIOLASE, Inc. :BIOL-US: Earnings Analysis: Q2, 2017 By the Numbers : August 16, 2017 (finance.yahoo.com)
BIOL has been the topic of several recent analyst reports. Singular Research initiated coverage on shares of Biolase in a research report on Tuesday, April 25th. They set a “buy” rating and a $2.50 price objective on the stock. ValuEngine downgraded shares of Biolase from a “hold” rating to a “sell” rating in a research report on Monday, July 24th.
Shares of Biolase (BIOL) traded up 0.50% during mid-day trading on Friday, reaching $0.60. 127,747 shares of the company traded hands. Biolase has a 52 week low of $0.48 and a 52 week high of $1.98. The stock’s market capitalization is $45.59 million. The firm has a 50 day moving average of $0.80 and a 200-day moving average of $1.16.
Biolase (NASDAQ:BIOL) last posted its earnings results on Monday, August 7th. The medical technology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by $0.04. Biolase had a negative net margin of 31.64% and a negative return on equity of 64.44%. The company had revenue of $12.61 million during the quarter. On average, equities research analysts expect that Biolase will post ($0.16) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This report was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/20/biolase-biol-earning-somewhat-negative-media-coverage-report-finds.html.
Biolase Company Profile
BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.
Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
